MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

To join this study, you must be 18 years or older and have a confirmed diagnosis of pleural mesothelioma that has spread and cannot be treated with surgery. Your cancer's specific type (epithelioid or non-epithelioid) must be known.

You also need to be generally well enough to participate in a clinical trial. This is assessed by doctors using a standard measure called the WHO/ECOG performance status. You need to have a score of 0 or 1, meaning you're quite active and able to look after yourself, with your health not having worsened in the two weeks before starting the study. Your body's organs, like your kidneys and liver, and your bone marrow, need to be working well, and your cancer needs to be measurable so doctors can track its response to treatment.

There are also some reasons why you might not be able to join. These include certain autoimmune diseases, other types of cancer you've had in the past (with some exceptions), or uncontrolled infections like tuberculosis, hepatitis, or HIV. You also can't be receiving other cancer treatments at the same time, or have untreated brain metastases (cancer that has spread to the brain). The study doctors will carefully review your health to make sure it's safe for you to take part.

If you decide to take part in this study, you'll first have a screening visit to check if you meet all the requirements. If you do, you'll be randomly assigned to receive one of the study treatments. This means you won't get to choose which treatment you receive; it's decided by chance, like flipping a coin, to ensure fairness in the study. You will receive either the new drug combination (Volrustomig + Carboplatin + Pemetrexed) or one of the standard treatments (either platinum + Pemetrexed or Nivolumab + Ipilimumab).

Throughout the study, you'll have regular visits to the hospital or clinic. During these visits, doctors and nurses will give you your study medication, conduct physical examinations, take blood samples, and perform imaging scans (like CT scans) to monitor your health and how the treatment is affecting your cancer. They will also ask you questions about any side effects you might be experiencing. The exact number and frequency of visits will depend on the specific treatment you receive, but you can expect several appointments over many months. After your main treatment period, there will be a follow-up period where your health will continue to be monitored.